INBS
Intelligent Bio Solutions Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.23
−3.04%Sep 2, 2026, 21:06 UTC
Intelligent Bio Solutions Inc. signed a securities purchase agreement on August 31, 2026, to sell 2,036,659 shares of common stock (or pre-funded warrants) with accompanying Series N-1 and N-2 warrants at a combined price of $2.455 per share, raising gross proceeds of approximately $5.0 million in a private placement to a single institutional investor.
Aug 19, 2026, 12:30 UTC
Intelligent Bio Solutions reported fiscal 2026 full-year revenue growth of 38% year-over-year, driven by reader installed base and high-margin cartridge growth.
Source:Aug 17, 2026, 19:43 UTC
Intelligent Bio Solutions Inc. announced a significant regulatory milestone for its rapid testing unit, causing its shares to surge on Monday.
Source:Aug 3, 2026, 12:30 UTC
Intelligent Bio Solutions completed an interference study for its Intelligent Fingerprinting Drug Screening System to support its FDA 510(k) submission for U.S. market clearance for opiate codeine detection.
Jun 2, 2026, 12:30 UTC
Intelligent Bio Solutions initiated a multi-site Method Comparison Study to support FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System for opiate codeine.
Source: